e-learning
resources
Paris 2018
Tuesday, 18.09.2018
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats
X. Cui (Wuhan, China), Z. Peng (Wuhan, China), Y. Zhou (Wuhan, China), H. Zhang (Wuhan, China), K. Lipson (San Francisco, United States of America), Y. Liu (Wuhan, China)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session:
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session type:
Poster Discussion
Number:
3666
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
X. Cui (Wuhan, China), Z. Peng (Wuhan, China), Y. Zhou (Wuhan, China), H. Zhang (Wuhan, China), K. Lipson (San Francisco, United States of America), Y. Liu (Wuhan, China). Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats. 3666
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010
Enhanced lung inflammatory response to intratracheal CpG-ODN in mice with bleomycin-induced lung fibrosis
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats
Source: Eur Respir J 2003 Dec 01;22(6):900-905
Year: 2003
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
Source: Eur Respir J 2001; 17: 1228-1235
Year: 2001
Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse
Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis
Year: 2010
Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Rikkunshito ameliorates bleomycin-induced lung injury in mice
Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Year: 2012
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis.
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
Chronic intermittent hypoxia exacerbates lung fibrosis in bleomycin-induced lung injury mouse model
Source: International Congress 2018 – Sleep-disordered breathing: cardiovascular consequences, epidemiology, phenotypes and comorbidities
Year: 2018
Time-course analysis of bleomycin-induced lung fibrosis in the rat
Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Year: 2018
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
Dexamethasone inhibits surfactant degradation during bleomycin-induced lung injury in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 855s
Year: 2006
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
Surface enolase-1 mediated cell migration and lung fibrosis in bleomycin-induced mice
Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Year: 2021
The role of osteopontin in the pulmonary fibrosis caused by acute lung injury induced by lipopolysaccharide in rats
Source: Annual Congress 2011 - Acute respiratory failure
Year: 2011
Rho-kinase inhibitor ameliorates bleomycin-induced chronic lung injury in neonatal rats
Source: Annual Congress 2011 - Issues in paediatric and neonatal intensive care
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept